16748 Federal Register / Vol. 87, No. 57 / Thursday, March 24, 2022 / Notices 

III. References 

The following references marked with 

an asterisk (*) are on display at the 

Dockets Management Staff (HFA–305), 

Food and Drug Administration, 5630 

Fishers Lane, Rm. 1061, Rockville, MD 

20852, 240–402–7500, and are available 

for viewing by interested persons 

between 9 a.m. and 4 p.m., Monday 

through Friday; they also are available 

electronically at https://

www.regulations.gov. References 

without asterisks are not on public 

display at https://www.regulations.gov 

because they have copyright restriction. 

Some may be available at the website 

address, if listed. References without 

asterisks are available for viewing only 

at the Dockets Management Staff. FDA 

has verified the website addresses, as of 

the date this document publishes in the 

Federal Register, but websites are 

subject to change over time. 

1. Beaver J.A., L.J. Howie, L. Pelosof, et al., 

‘‘A 25-Year Experience of U.S. Food and 

Drug Administration Accelerated 

Approval of Malignant Hematology and 

Oncology Drugs and Biologics: A 

Review.’’ JAMA Oncology. 2018; 

4(6):849–856. 

2. Sullivan H.W., A.C. O’Donoghue, K.T. 

David, et al., ‘‘Disclosing Accelerated 

Approval on Direct-to-Consumer 

Prescription Drug websites.’’ 

Pharmacoepidemiology and Drug Safety. 

2018;27:1277–1280. https://doi.org/ 

10.1002/pds.4664. 

3. Cutrona, S.L., K.M. Mazor, S.N. Vieux, et 

al., ‘‘Health Information-Seeking on 

Behalf of Others: Characteristics of 

‘Surrogate Seekers’.’’ Journal of Cancer 

Education. 2015;30:12–19. https://

www.ncbi.nlm.nih.gov/pmc/articles/ 

PMC4282983/. 

4. Sadasivam, R.S., R.L. Kinney, S.C. Lemon, 

et al., ‘‘Internet Health Information 

Seeking Is a Team Sport: Analysis of the 

Pew Internet Survey.’’ International 

Journal of Medical Informatics. 

2013;82:193–200. 

* 5. Bangerter, L.R., J. Griffin, K. Harden, et 

al., ‘‘Health Information-Seeking 

Behaviors of Family Caregivers: Analysis 

of the Health Information National 

Trends Survey.’’ JMIR Aging. 

2019;2:e11237. https://aging.jmir.org/ 

2019/1/e11237/. 

6. von Itzstein, M.S., E. Railey, M.L. Smith, 

et al., ‘‘Patient Familiarity with, 

Understanding of, and Preferences for 

Clinical Trial Endpoints and 

Terminology.’’ Cancer. 2021;126:1605– 

1613. 

7. Kelly, B.J., D.J. Rupert, K.J. Aikin, et al., 

‘‘Development and Validation of 

Prescription Drug Risk, Efficacy, and 

Benefit Perception Measures in the 

Context of Direct-to-Consumer 

Prescription Drug Advertising.’’ 

Research in Social and Administrative 

Pharmacy. 2021;17:942–955. 

Dated: March 17, 2022. 

Andi Lipstein Fristedt, 

Deputy Commissioner for Policy, Legislation, 

and International Affairs, U.S. Food and Drug 

Administration. 

[FR Doc. 2022–06220 Filed 3–23–22; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

National Vaccine Injury Compensation 

Program; List of Petitions Received 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: HRSA is publishing this 

notice of petitions received under the 

National Vaccine Injury Compensation 

Program (the Program), as required by 

Section 2112(b)(2) of the Public Health 

Service (PHS) Act, as amended. While 

the Secretary of HHS is named as the 

respondent in all proceedings brought 

by the filing of petitions for 

compensation under the Program, the 

United States Court of Federal Claims is 

charged by statute with responsibility 

for considering and acting upon the 

petitions. 

FOR FURTHER INFORMATION CONTACT: For 

information about requirements for 

filing petitions, and the Program in 

general, contact Lisa L. Reyes, Clerk of 

Court, United States Court of Federal 

Claims, 717 Madison Place NW, 

Washington, DC 20005, (202) 357–6400. 

For information on HRSA’s role in the 

Program, contact the Director, National 

Vaccine Injury Compensation Program, 

5600 Fishers Lane, Room 08N146B, 

Rockville, Maryland 20857; (301) 443– 

6593, or visit our website at: http://

www.hrsa.gov/vaccinecompensation/ 

index.html. 

SUPPLEMENTARY INFORMATION: The 

Program provides a system of no-fault 

compensation for certain individuals 

who have been injured by specified 

childhood vaccines. Subtitle 2 of Title 

XXI of the PHS Act, 42 U.S.C. 300aa– 

10 et seq., provides that those seeking 

compensation are to file a petition with 

the United States Court of Federal 

Claims and to serve a copy of the 

petition to the Secretary of HHS, who is 

named as the respondent in each 

proceeding. The Secretary has delegated 

this responsibility under the Program to 

HRSA. The Court is directed by statute 

to appoint special masters who take 

evidence, conduct hearings as 

appropriate, and make initial decisions 

as to eligibility for, and amount of, 

compensation. 

A petition may be filed with respect 

to injuries, disabilities, illnesses, 

conditions, and deaths resulting from 

vaccines described in the Vaccine Injury 

Table (the Table) set forth at 42 CFR 

100.3. This Table lists for each covered 

childhood vaccine the conditions that 

may lead to compensation and, for each 

condition, the time period for 

occurrence of the first symptom or 

manifestation of onset or of significant 

aggravation after vaccine 

administration. Compensation may also 

be awarded for conditions not listed in 

the Table and for conditions that are 

manifested outside the time periods 

specified in the Table, but only if the 

petitioner shows that the condition was 

caused by one of the listed vaccines. 

Section 2112(b)(2) of the PHS Act, 42 

U.S.C. 300aa–12(b)(2), requires that 

‘‘[w]ithin 30 days after the Secretary 

receives service of any petition filed 

under section 2111 the Secretary shall 

publish notice of such petition in the 

Federal Register.’’ Set forth below is a 

list of petitions received by HRSA on 

February 1, 2022, through February 28, 

2022. This list provides the name of 

petitioner, city and state of vaccination 

(if unknown then city and state of 

person or attorney filing claim), and 

case number. In cases where the Court 

has redacted the name of a petitioner 

and/or the case number, the list reflects 

such redaction. 

Section 2112(b)(2) also provides that 

the special master ‘‘shall afford all 

interested persons an opportunity to 

submit relevant, written information’’ 

relating to the following: 

1. The existence of evidence ‘‘that 

there is not a preponderance of the 

evidence that the illness, disability, 

injury, condition, or death described in 

the petition is due to factors unrelated 

to the administration of the vaccine 

described in the petition,’’ and 

2. Any allegation in a petition that the 

petitioner either: 

a. ‘‘[S]ustained, or had significantly 

aggravated, any illness, disability, 

injury, or condition not set forth in the 

Vaccine Injury Table but which was 

caused by’’ one of the vaccines referred 

to in the Table, or 

b. ‘‘[S]ustained, or had significantly 

aggravated, any illness, disability, 

injury, or condition set forth in the 

Vaccine Injury Table the first symptom 

or manifestation of the onset or 

significant aggravation of which did not 

occur within the time period set forth in 

the Table but which was caused by a 

vaccine’’ referred to in the Table. 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 57 / Thursday, March 24, 2022 / Notices 16749 

In accordance with Section 

2112(b)(2), all interested persons may 

submit written information relevant to 

the issues described above in the case of 

the petitions listed below. Any person 

choosing to do so should file an original 

and three (3) copies of the information 

with the Clerk of the United States 

Court of Federal Claims at the address 

listed above (under the heading FOR

FURTHER INFORMATION CONTACT), with a 

copy to HRSA addressed to Director, 

Division of Injury Compensation 

Programs, Health Systems Bureau, 5600 

Fishers Lane, 08N146B, Rockville, 

Maryland 20857. The Court’s caption 

(Petitioner’s Name v. Secretary of HHS) 

and the docket number assigned to the 

petition should be used as the caption 

for the written submission. Chapter 35 

of title 44, United States Code, related 

to paperwork reduction, does not apply 

to information required for purposes of 

carrying out the Program. 

Carole Johnson, 

Administrator. 

List of Petitions Filed 

1. Michelle Davis on behalf of A.D., 

Phoenix, Arizona, Court of Federal 

Claims No: 22–0098V 

2. Barbara Sciortino, Las Vegas, Nevada, 

Court of Federal Claims No: 22– 

0099V 

3. Ruby Sharma Dhital, West Hartford, 

Connecticut, Court of Federal 

Claims No: 22–0101V 

4. Chelsea Smith on behalf of C.S., 

Danville, Kentucky, Court of 

Federal Claims No: 22–0103V 

5. Brechen Santeramo, Fort Collins, 

Colorado, Court of Federal Claims 

No: 22–0104V 

6. Shawn Geiger, Hackettstown, New 

Jersey, Court of Federal Claims No: 

22–0106V 

7. Roberta Johnson, Winfield, Illinois, 

Court of Federal Claims No: 22– 

0107V 

8. Samuel Martin, Oklahoma City, 

Oklahoma, Court of Federal Claims 

No: 22–0109V 

9. Marijane Angels, Southington, 

Connecticut, Court of Federal 

Claims No: 22–0112V 

10. Suzanne Kallin, Los Angeles, 

California, Court of Federal Claims 

No: 22–0113V 

11. Maria Sims, Philadelphia, 

Pennsylvania, Court of Federal 

Claims No: 22–0115V 

12. Karen Miller, Seattle, Washington, 

Court of Federal Claims No: 22– 

0116V 

13. Jerry Brown, Greenville, Texas, 

Court of Federal Claims No: 22– 

0118V 

14. Demetrius Lockett, Detroit, 

Michigan, Court of Federal Claims 

No: 22–0119V 

15. Pamela Allen, Fairburn, Georgia, 

Court of Federal Claims No: 22– 

0122V 

16. Ann Marie Indorf on behalf of K.I., 

Phoenix, Arizona, Court of Federal 

Claims No: 22–0123V 

17. Dana Mowery, Delaware, Ohio, 

Court of Federal Claims No: 22– 

0124V 

18. Ronald L. Jopes, Elizabethtown, 

Kentucky, Court of Federal Claims 

No: 22–0125V 

19. Anne Rosenthal, Palo Alto, 

California, Court of Federal Claims 

No: 22–0126V 

20. Joan Steede, Rockford, Illinois, Court 

of Federal Claims No: 22–0128V 

21. Andrew Short, St. Paul, Minnesota, 

Court of Federal Claims No: 22– 

0129V 

22. Herbert St. Amant, Cypress, 

California, Court of Federal Claims 

No: 22–0130V 

23. Norman Michaud, Auburn, Maine, 

Court of Federal Claims No: 22– 

0134V 

24. Jordanna Ross, La Porte, Indiana, 

Court of Federal Claims No: 22– 

0136V 

25. Gary Krugel, Antigo, Wisconsin, 

Court of Federal Claims No: 22– 

0139V 

26. CarolAnn Sinclair, Anacortes, 

Washington, Court of Federal 

Claims No: 22–0140V 

27. Sheetal Paliwal, Libertyville, 

Illinois, Court of Federal Claims No: 

22–0141V 

28. Jonessa Casarez on behalf of A.C., 

Phoenix, Arizona, Court of Federal 

Claims No: 22–0142V 

29. Hunter Miller, Phoenix, Arizona, 

Court of Federal Claims No: 22– 

0143V 

30. Kelly Quinn, Tempe, Arizona, Court 

of Federal Claims No: 22–0144V 

31. Mary Walsh, Valatie, New York, 

Court of Federal Claims No: 22– 

0148V 

32. Arnold Saitow, Boston, 

Massachusetts, Court of Federal 

Claims No: 22–0150V 

33. Zachary Hemenway, Staples, 

Minnesota, Court of Federal Claims 

No: 22–0153V 

34. John Owen, West Des Moines, Iowa, 

Court of Federal Claims No: 22– 

0155V 

35. Jordan Aguilar, Phoenix, Arizona, 

Court of Federal Claims No: 22– 

0156V 

36. Jean Deoleo and Dayre Deoleo on 

behalf of I.D., Miami, Florida, Court 

of Federal Claims No: 22–0157V 

37. Nanoya Burgan, Lawrenceville, 

Georgia, Court of Federal Claims 

No: 22–0158V 

38. Mary White on behalf of M.A., 

Phoenix, Arizona, Court of Federal 

Claims No: 22–0159V 

39. Muriel J. Duval, Las Vegas, Nevada, 

Court of Federal Claims No: 22– 

0160V 

40. Florence Barrett, Tacoma, 

Washington, Court of Federal 

Claims No: 22–0161V 

41. Ljubitza Ghiardi, Phoenix, Arizona, 

Court of Federal Claims No: 22– 

0162V 

42. Clara Nickels, Phoenix, Arizona, 

Court of Federal Claims No: 22– 

0167V 

43. Denise Warburton on behalf of C.C., 

Phoenix, Arizona, Court of Federal 

Claims No: 22–0169V 

44. Sandra Fox, Pittsburgh, 

Pennsylvania, Court of Federal 

Claims No: 22–0176V 

45. Alexis Dimick, Phoenix, Arizona, 

Court of Federal Claims No: 22– 

0188V 

46. Jacki Della Rosa Carron, Upper 

Arlington, Ohio, Court of Federal 

Claims No: 22–0189V 

47. Matthew J. Miller, Fairbury, 

Nebraska, Court of Federal Claims 

No: 22–0190V 

48. Tiara Pore, New Hyde Park, New 

York, Court of Federal Claims No: 

22–0191V 

49. Cheryl A. Maxheimer, Fenton, 

Michigan, Court of Federal Claims 

No: 22–0192V 

50. Kari Lynn Fisher, Port Angeles, 

Washington, Court of Federal 

Claims No: 22–0195V 

51. Mira Goff on behalf of the Estate of 

Richard Goff, Deceased, Kenton, 

Ohio, Court of Federal Claims No: 

22–0199V 

52. Gregory Mills, Texas City, Texas, 

Court of Federal Claims No: 22– 

0203V 

53. Teresa Vickers on behalf of the 

Estate of Wanda Sovine, Deceased, 

Hurricane, West Virginia, Court of 

Federal Claims No: 22–0204V 

54. Larry Toothman, East Liverpool, 

Ohio, Court of Federal Claims No: 

22–0207V 

55. Danette Weems, St. Louis, Missouri, 

Court of Federal Claims No: 22– 

0208V 

56. Amelia Goff, Eufaula, Alabama, 

Court of Federal Claims No: 22– 

0209V 

57. Sabine Templeton on behalf of the 

Estate of Ramsay Templeton, 

Deceased, Fernandina Beach, 

Florida, Court of Federal Claims No: 

22–0210V 

58. Mark Cunningham, Charlotte, North 

Carolina, Court of Federal Claims 

No: 22–0211V 

59. Bret Wood, Concord, North Carolina, 

Court of Federal Claims No: 22– 

0212V 


khammond on DSKJM1Z7X2PROD with NOTICES
16750 Federal Register / Vol. 87, No. 57 / Thursday, March 24, 2022 / Notices 

60. Fahtima Isaac, Phoenix, Arizona, 

Court of Federal Claims No: 22– 

0213V 

61. Shannon McDonald, Lumberton, 

New Jersey, Court of Federal Claims 

No: 22–0215V 

62. Anita Enns, Katy, Texas, Court of 

Federal Claims No: 22–0216V 

63. Joyce Glenn on behalf of the Estate 

of Anthony Glenn, Deceased, 

Fontana, California, Court of 

Federal Claims No: 22–0217V 

64. April Keen, Greenville, South 

Carolina, Court of Federal Claims 

No: 22–0218V 

65. Carey Cribbs, Ferndale, Michigan, 

Court of Federal Claims No: 22– 

0219V 

66. Sara Davis Buechner, Philadelphia, 

Pennsylvania, Court of Federal 

Claims No: 22–0220V 

67. Rafael Mauries, Cedar Park, Texas, 

Court of Federal Claims No: 22– 

0224V 

[FR Doc. 2022–06249 Filed 3–23–22; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Tick-Borne Disease 

Working Group 

AGENCY: Office of the Assistant 

Secretary for Health, Office of the 

Secretary, Department of Health and 

Human Services. 

ACTION: Notice. 

SUMMARY: As required by the Federal 

Advisory Committee Act, the 

Department of Health and Human 

Services (HHS) is hereby giving notice 

that the Tick-Borne Disease Working 

Group (TBDWG) will hold a virtual 

meeting. The meeting will be open to 

the public. For this meeting, the 

TBDWG will be discussing and voting 

on recommendations for the 2022 

TBDWG Report to the HHS Secretary 

and Congress. Most of the 

recommendations the TBDWG will 

consider are from the reports of five 

TBDWG subcommittees, which were 

created to examine critical topic areas 

related to tick-borne diseases. The 2022 

report will address a wide range of 

topics related to tick-borne diseases, 

such as, surveillance, prevention, 

diagnosis, diagnostics, and treatment; 

identify advances made in research, as 

well as overlap and gaps in tick-borne 

disease research; and provide 

recommendations regarding any 

appropriate changes or improvements to 

such activities and research. 

DATES: The meeting will be held online 

via webcast on April 27, 2022–April 28, 

2022 from approximately 9:00 a.m. to 

5:00 p.m. ET (times are tentative and 

subject to change) each day. The 

confirmed times and agenda items for 

the meeting will be posted on the 

TBDWG web page https://www.hhs.gov/ 

ash/advisory-committees/tickborne

disease/meetings/2022-04-27/ 

index.html when this information 

becomes available. 

FOR FURTHER INFORMATION CONTACT: 

James Berger, Designated Federal Officer 

for the TBDWG; Office of Infectious 

Disease and HIV/AIDS Policy, Office of 

the Assistant Secretary for Health, 

Department of Health and Human 

Services, Mary E. Switzer Building, 330 

C Street SW, Suite L600, Washington, 

DC 20024. Email: tickbornedisease@

hhs.gov. Phone: 202–795–7608. 

SUPPLEMENTARY INFORMATION: 

Registration information can be found 

on the meeting website at https://

www.hhs.gov/ash/advisory-committees/ 

tickbornedisease/meetings/2022-04-27/ 

index.html when it becomes available. 

The public will have an opportunity to 

present their views to the TBDWG orally 

during the meeting’s public comment 

session or by submitting a written 

public comment. Comments should be 

pertinent to the meeting discussion. 

Persons who wish to provide verbal or 

written public comment should review 

instructions at https://www.hhs.gov/ 

ash/advisory-committees/tickborne

disease/meetings/2022-04-27/ 

index.html and respond by midnight 

April 15, 2022 ET. Verbal comments 

will be limited to three minutes each to 

accommodate as many speakers as 

possible during the 30 minute session. 

Written public comments will be 

accessible to the public on the TBDWG 

web page prior to the meeting. 

Background and Authority: The TickBorne Disease Working Group was 

established on August 10, 2017, in 

accordance with Section 2062 of the 

21st Century Cures Act, and the Federal 

Advisory Committee Act, 5 U.S.C. App., 

as amended, to provide expertise and 

review federal efforts related to all tickborne diseases, to help ensure 

interagency coordination and minimize 

overlap, and to examine research 

priorities. The TBDWG is required to 

submit a report to the HHS Secretary 

and Congress on their findings and any 

recommendations for the federal 

response to tick-borne disease every two 

years. 

Dated: March 14, 2022. 

James J. Berger, 

Designated Federal Officer, Tick-Borne 

Disease Working Group, Office of Infectious 

Disease and HIV/AIDS Policy. 

[FR Doc. 2022–06226 Filed 3–23–22; 8:45 am] 

BILLING CODE 4150–28–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Findings of research 

misconduct have been made against Hui 

(Herb) Bin Sun, Ph.D. (Respondent), 

formerly Professor of Orthopedic 

Surgery and Radiation Oncology, Albert 

Einstein College of Medicine (AECM). 

Respondent engaged in research 

misconduct in research supported by 

U.S. Public Health Service (PHS) funds, 

specifically National Institute of 

Arthritis and Musculoskeletal and Skin 

Diseases (NIAMS), National Institutes of 

Health (NIH), grant R01 AR050968 and 

National Heart, Lung, and Blood 

Institute (NHLBI), NIH, grant P01 

HL110900. The administrative actions, 

including supervision for a period of 

twelve (12) years, were implemented 

beginning on March 1, 2022, and are 

detailed below. 

FOR FURTHER INFORMATION CONTACT: 

Wanda K. Jones, Dr.P.H., Acting 

Director, Office of Research Integrity, 

1101 Wootton Parkway, Suite 240, 

Rockville, MD 20852, (240) 453–8200. 

SUPPLEMENTARY INFORMATION: Notice is 

hereby given that the Office of Research 

Integrity (ORI) has taken final action in 

the following case: 

Hui (Herb) Bin Sun, Ph.D., Albert 

Einstein College of Medicine: Based on 

the report of an investigation conducted 

by AECM and analysis conducted by 

ORI in its oversight review, ORI found 

that Dr. Sun, formerly Professor of 

Orthopedic Surgery and Radiation 

Oncology, AECM, engaged in research 

misconduct in research supported by 

PHS funds, specifically NIAMS, NIH, 

grant R01 AR050968 and NHLBI, NIH, 

grant P01 HL110900. 

ORI found that Respondent engaged 

in research misconduct by intentionally, 

knowingly, or recklessly falsifying and/ 

or fabricating data included in sixteen 

(16) grant applications submitted for 

PHS funds: 

• R01 AR065563–01, ‘‘CITED2 and 

Chondroprotection,’’ submitted to 

NIAMS, NIH, on 02/05/2013. 


khammond on DSKJM1Z7X2PROD with NOTICES